Treatment of Cachexia. Melanocortin and Ghrelin Interventions.

Vitamins and Hormones

Volumn 92, Issue , 2013, Pages 197-242

  Steinman, Jeremy ^a   DeBoer, Mark Daniel ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Anorexia; Cachexia; Cancer; Chronic heart failure; Chronic kidney disease; Cytokines; Ghrelin; MC4R; Melanocortin

Indexed keywords

EID: 84876805143     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-410473-0.00008-8     Document Type: Chapter

References (265)

1. Adachi S., Takiguchi S., Okada K., Yamamoto K., Yamasaki M., Miyata H., et al. Effects of ghrelin administration after total gastrectomy: A prospective, randomized, placebo-controlled phase II study. Gastroenterology 2010, 138:1312-1320.
2. Akashi Y.J., Palus S., Datta R., Halem H., Taylor J.E., Thoene-Reineke C., et al. No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. International Journal of Cardiology 2009, 137:267-275.
3. Alvarez-Rodriguez L., Lopez-Hoyos M., Munoz-Cacho P., Martinez-Taboada V.M. Aging is associated with circulating cytokine dysregulation. Cellular Immunology 2012, 273:124-132.
4. Anker S. European perspectives. Circulation 2006, 113:f53-f56.
5. Anker S.D., Chua T.P., Ponikowski P., Harrington D., Swan J.W., Kox W.J., et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997, 96:526-534.
6. Anker S.D., Coats A.J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. International Journal of Cardiology 2002, 86:123-130.
7. Anker S.D., Egerer K.R., Volk H.-D., Kox W.J., Poole-Wilson P.A., Coats A.J.S. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. The American Journal of Cardiology 1997, 79:1426-1430.
8. Anker S.D., Ponikowski P., Varney S., Chua T.P., Clark A.L., Webb-Peploe K.M., et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997, 349:1050-1053.
9. Anker S.D., Sharma R. The syndrome of cardiac cachexia. International Journal of Cardiology 2002, 85:51-66.
10. Ariyasu H., Iwakura H., Yamada G., Nakao K., Kangawa K., Akamizu T. Efficacy of ghrelin as a therapeutic approach for age-related physiological changes. Endocrinology 2008, 149:3722-3728.
11. Arques S., Ambrosi P. Human serum albumin in the clinical syndrome of heart failure. Journal of Cardiac Failure 2011, 17:451-458.
12. Arruda A.P., Milanski M., Romanatto T., Solon C., Coope A., Alberici L.C., et al. Hypothalamic actions of tumor necrosis factor α provide the thermogenic core for the wastage syndrome in cachexia. Endocrinology 2010, 151:683-694.
13. Asakawa A., Inui A., Kaga T., Katsuura G., Fujimiya M., Fujino M.A., et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003, 52:947-952.
14. Ashby D.R., Ford H.E., Wynne K.J., Wren A.M., Murphy K.G., Busbridge M., et al. Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney International 2009, 76:199-206.
15. Asher V., Lee J., Bali A. Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Medical Oncology (Northwood, London, England) 2011, 29:2005-2009.
16. Ashitani J.-i., Matsumoto N., Nakazato M. Ghrelin and its therapeutic potential for cachectic patients. Peptides 2009, 30:1951-1956.
17. Ates Y., Degertekin B., Erdil A., Yaman H., Dagalp K. Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Digestive Diseases and Sciences 2008, 53:2215-2221.
18. Balasubramaniam A., Joshi R., Su C., Friend L.A., Sheriff S., Kagan R.J., et al. Ghrelin inhibits skeletal muscle protein breakdown in rats with thermal injury through normalizing elevated expression of E3 ubiquitin ligases MuRF1 and MAFbx. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2009, 296:R893-R901.
19. Balasubramaniam A., Wood S., Joshi R., Su C., Friend L.A., Sheriff S., et al. Ghrelin stimulates food intake and growth hormone release in rats with thermal injury: Synthesis of ghrelin. Peptides 2006, 27:1624-1631.
20. Barber M.D., Fearon K.C., Tisdale M.J., McMillan D.C., Ross J.A. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutrition and Cancer 2001, 40:118-124.
21. Barber M.D., Preston T., McMillan D.C., Slater C., Ross J.A., Fearon K.C. Modulation of the liver export protein synthetic response to feeding by an n-3 fatty-acid-enriched nutritional supplement is associated with anabolism in cachectic cancer patients. Clinical Science (London, England) 2004, 106:359-364.
22. Barreiro M.L., Tena-Sempere M. Ghrelin and reproduction: A novel signal linking energy status and fertility?. Molecular and Cellular Endocrinology 2004, 226:1-9.
23. Baumann H., Gauldie J. The acute phase response. Immunology Today 1994, 15:74-80.
24. Beberashvili I., Sinuani I., Azar A., Yasur H., Feldman L., Averbukh Z., et al. Longitudinal study of leptin levels in chronic hemodialysis patients. Nutrition Journal 2011, 10:68.
25. Bennani-Baiti N., Davis M.P. Cytokines and cancer anorexia cachexia syndrome. The American Journal of Hospice & Palliative Care 2008, 25:407-411.
26. Berenstein E.G., Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Systematic Reviews 2005, 18(2):CD004310.
27. Bergstrom J. Why are dialysis patients malnourished?. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation 1995, 26:229-241.
28. Blaha V., Yang Z.J., Meguid M.M., Chai J.K., Oler A., Zadak Z. Ventromedial nucleus of hypothalamus is related to the development of cancer-induced anorexia: in vivo microdialysis study. Acta Medica (Hradec Kralove)/Universitas Carolina, Facultas Medica Hradec Kralove 1998, 41:3-11.
29. Bober L.A., Rojas-Triana A., Jackson J.V., Leach M.W., Manfra D., Narula S.K., et al. Regulatory effects of interleukin-4 and interleukin-10 on human neutrophil function ex vivo and on neutrophil influx in a rat model of arthritis. Arthritis and Rheumatism 2000, 43:2660-2667.
30. Bossola M., Tazza L., Giungi S., Luciani G. Anorexia in hemodialysis patients: An update. Kidney International 2006, 70:417-422.
31. Braissant O., Foufelle F., Scotto C., Dauça M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137:354-366.
32. Buscher A.K., Buscher R., Hauffa B.P., Hoyer P.F. Alterations in appetite-regulating hormones influence protein-energy wasting in pediatric patients with chronic kidney disease. Pediatric Nephrology (Berlin, Germany) 2010, 25:2295-2301.
33. Butler A.A., Cone R.D. The melanocortin receptors: Lessons from knockout models. Neuropeptides 2002, 36:77-84.
34. Cannon T., Couch M., Yin X., Guttridge D., Lai V., Shores C. Comparison of animal models for head and neck cancer cachexia. The Laryngoscope 2007, 117:2152-2158.
35. Carrero J.J., Nakashima A., Qureshi A.R., Lindholm B., Heimburger O., Barany P., et al. Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney International 2011, 79:749-756.
36. Carroll G., Bell M., Wang H., Chapman H., Mills J. Antagonism of the IL-6 cytokine subfamily-A potential strategy for more effective therapy in rheumatoid arthritis. Inflammation Research: Official Journal of the European Histamine Research Society... [et al.] 1998, 47:1-7.
37. Carson J.A., Baltgalvis K.A. Interleukin 6 as a Key regulator of muscle mass during cachexia. Exercise and Sport Sciences Reviews 2010, 38:168-176.
38. Chance W.T., Balasubramaniam A., Dayal R., Brown J., Fischer J.E. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. Life Sciences 1994, 54:1869-1874.
39. Chen M.-C., Chang H.-W., Wu C.-J., Yang C.-H., Yu T.-H., Chen C.-J., et al. Balance between plasma levels of tumor necrosis factor-[alpha] and interleukin-10 in rheumatic mitral stenosis. Cardiology 2005, 104:171-175.
40. Chen C., Tucci F.C., Jiang W., Tran J.A., Fleck B.A., Hoare S.R., et al. Pharmacological and pharmacokinetic characterization of 2-piperazine-α-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorganic & Medicinal Chemistry 2008, 16:5606-5618.
41. Cheung C.C., Clifton D.K., Steiner R.A. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 1997, 138:4489-4492.
42. Cheung W.W., Kuo H.-J., Markison S., Chen C., Foster A.C., Marks D.L., et al. Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice. Journal of the American Society of Nephrology 2007, 18:2517-2524.
43. Cheung W.W., Rosengren S., Boyle D.L., Mak R.H. Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney International 2008, 74:180-186.
44. Cheung W., Yu P.X., Little B.M., Cone R.D., Marks D.L., Mak R.H. Role of leptin and melanocortin signaling in uremia-associated cachexia. The Journal of Clinical Investigation 2005, 115:1659-1665.
45. Cheunsuang O., Morris R. Astrocytes in the arcuate nucleus and median eminence that take up a fluorescent dye from the circulation express leptin receptors and neuropeptide Y Y1 receptors. Glia 2005, 52:228-233.
46. Chopin L., Walpole C., Seim I., Cunningham P., Murray R., Whiteside E., et al. Ghrelin and cancer. Molecular and Cellular Endocrinology 2011, 340:65-69.
47. Choy E.H.S., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. The New England Journal of Medicine 2001, 344:907-916.
48. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T., Anti T.N.F.T.A.C.H.F.I. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003, 107:3133-3140.
49. ClinicalTrials.gov. (2012a). Search of: Cachexia LIF-Search Details-ClinicalTrials.gov.
50. ClinicalTrials.gov. (2012b). Search of: Cachexia melanocortin-Search Details-ClinicalTrials.gov.
51. ClinicalTrials.gov. (2012c). Search of: Melanocortin 4 receptor antagonist-Search Details-ClinicalTrials.gov.
52. Cone R.D. Anatomy and regulation of the central melanocortin system. Nature Neuroscience 2005, 8:571-578.
53. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., et al. Valvular heart disease associated with fenfluramine-Phentermine. The New England Journal of Medicine 1997, 337:581-588.
54. Cornish J., Callon K., King A., Edgar S., Reid I.R. The effect of leukemia inhibitory factor on bone in vivo. Endocrinology 1993, 132:1359-1366.
55. Cowley M.A., Pronchuk N., Fan W., Dinulescu D.M., Colmers W.F., Cone R.D. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: Evidence of a cellular basis for the adipostat. Neuron 1999, 24:155-163.
56. Cowley M.A., Smart J.L., Rubinstein M., Cerdan M.G., Diano S., Horvath T.L., et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001, 411:480-484.
57. Cowley M.A., Smith R.G., Diano S., Tschop M., Pronchuk N., Grove K.L., et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003, 37:649-661.
58. Cui R.J., Li X., Appleyard S.M. Ghrelin inhibits visceral afferent activation of catecholamine neurons in the solitary tract nucleus. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2011, 31:3484-3492.
59. Cunningham J. Body composition as a determinant of energy expenditure: A synthetic review and a proposed general prediction equation. The American Journal of Clinical Nutrition 1991, 54:963-969.
60. Dalla Libera L., Sabbadini R., Renken C., Ravara B., Sandri M., Betto R., et al. Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-α and sphingosine. Journal of Molecular and Cellular Cardiology 2001, 33:1871-1878.
61. Dallmann R., Weyermann P., Anklin C., Boroff M., Bray-French K., Cardel B., et al. The orally active melanocortin-4 receptor antagonist BL-6020/979: A promising candidate for the treatment of cancer cachexia. Journal of Cachexia Sarcopenia Muscle 2011, 2:163-174.
62. Dasu M.R.K., Cobb J.P., Laramie J.M., Chung T.P., Spies M., Barrow R.E. Gene expression profiles of livers from thermally injured rats. Gene 2004, 327:51-60.
63. Davis M.P., Dreicer R., Walsh D., Lagman R., LeGrand S.B. Appetite and cancer-associated anorexia: A review. Journal of Clinical Oncology 2004, 22:1510-1517.
64. Deans C., Wigmore S.J. Systemic inflammation, cachexia and prognosis in patients with cancer. Current Opinion in Clinical Nutrition and Metabolic Care 2005, 8:265-269.
65. DeBoer M.D. Melanocortin interventions in cachexia: How soon from bench to bedside?. Current Opinion in Clinical Nutrition and Metabolic Care 2007, 10:457-462. 10.1097/MCO.1090b1013e328108f328441.
66. DeBoer M.D. Emergence of ghrelin as a treatment for cachexia syndromes. Nutrition 2008, 24:806-814.
67. DeBoer M.D. Update on melanocortin interventions for cachexia: Progress toward clinical application (burbank, Los angeles county, calif.). Nutrition 2010, 26:146-151.
68. DeBoer M.D. Ghrelin and cachexia: Will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes?. Molecular and Cellular Endocrinology 2011, 340:97-105.
69. DeBoer M.D. Use of ghrelin as a treatment for inflammatory bowel disease: Mechanistic considerations. International Journal of Peptides 2011, 2011:189242.
70. DeBoer M.D., Marks D.L. Cachexia: Lessons from melanocortin antagonism. Trends in Endocrinology and Metabolism 2006, 17:199-204.
71. DeBoer M.D., Marks D.L. Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nature Clinical Practice, Endocrinology & Metabolism 2006, 2:459-466.
72. DeBoer M.D., Scarlett J.M., Levasseur P.R., Grant W.F., Marks D.L. Administration of IL-1beta to the 4th ventricle causes anorexia that is blocked by agouti-related peptide and that coincides with activation of tyrosine-hydroxylase neurons in the nucleus of the solitary tract. Peptides 2009, 30:210-218.
73. DeBoer M.D., Zhu X., Levasseur P.R., Inui A., Hu Z., Han G., et al. Ghrelin treatment of chronic kidney disease: Improvements in lean body mass and cytokine profile. Endocrinology 2008, 149:827-835.
74. DeBoer M.D., Zhu X.X., Levasseur P., Meguid M.M., Suzuki S., Inui A., et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a Rat model of cancer cachexia. Endocrinology 2007, 148:3004-3012.
75. Doering J.E., Kane K., Hsiao Y.-C., Yao C., Shi B., Slowik A.D., et al. Species differences in the expression of Ahi1, a protein implicated in the neurodevelopmental disorder joubert syndrome, with preferential accumulation to stigmoid bodies. The Journal of Comparative Neurology 2008, 511:238-256.
76. Donovan H. Malignant cachexia. Proceedings of the Royal Society of Medicine 1954, 47:27-31.
77. Dutka D.P., Elborn J.S., Delamere F., Shale D.J., Morris G.K. Tumour necrosis factor alpha in severe congestive cardiac failure. British Heart Journal 1993, 70:141-143.
78. Ersahin M., Toklu H.Z., Erzik C., Akakin D., Tetik S., Sener G., et al. Ghrelin alleviates spinal cord injury in rats via its anti-inflammatory effects. Turkish Neurosurgery 2011, 21:599-605.
79. Esposito J.G., Thomas S.G., Kingdon L., Ezzat S. Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: A randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 2004, 89:5124-5131.
80. Esposito J.G., Thomas S.G., Kingdon L., Ezzat S. Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting. American Journal of Physiology-Endocrinology and Metabolism 2005, 289:E494-E503.
81. Eylar E.H., Lefranc C., Baez I., Colon-Martinez S.L., Yamamura Y., Rodriguez N., et al. Enhanced interferon-[gamma] by CD8+ CD28- lymphocytes from HIV+patients. Journal of Clinical Immunology 2001, 21:135-144.
82. Falconer J.S., Fearon K.C., Ross J.A., Elton R., Wigmore S.J., Garden O.J., et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995, 75:2077-2082.
83. Fan W., Boston B.A., Kesterson R.A., Hruby V.J., Cone R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997, 385:165-168.
84. Farooqi I.S., Keogh J.M., Yeo G.S.H., Lank E.J., Cheetham T., O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. The New England Journal of Medicine 2003, 348:1085-1095.
85. Farooqi I.S., Yeo G.S., Keogh J.M., Aminian S., Jebb S.A., Butler G., et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. The Journal of Clinical Investigation 2000, 106:271-279.
86. Fearon K.C.H. The mechanisms and treatment of weight loss in cancer. The Proceedings of the Nutrition Society 1992, 51:251-265.
87. Fearon K.C., Carter D.C. Cancer cachexia. Annals of Surgery 1988, 208:1-5.
88. Fearon K.C., Von Meyenfeldt M.F., Moses A.G., Van Geenen R., Roy A., Gouma D.J., et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial. Gut 2003, 52:1479-1486.
89. Fearon K.C., Voss A.C., Hustead D.S., Cancer Cachexia Study Group Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. The American Journal of Clinical Nutrition 2006, 83:1345-1350.
90. Febbraio M.A. gp130 Receptor ligands as potential therapeutic targets for obesity. The Journal of Clinical Investigation 2007, 117:841-849.
91. Fiedler R., Mall M., Wand C., Osten B. Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. Journal of Renal Nutrition 2005, 15:253-256.
92. Fouladiun M., Korner U., Bosaeus I., Daneryd P., Hyltander A., Lundholm K.G. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care-Correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005, 103:2189-2198.
93. Frost R.A., Nystrom G.J., Lang C.H. Endotoxin and interferon-gamma inhibit translation in skeletal muscle cells by stimulating nitric oxide synthase activity. Shock 2009, 32:416-426.
94. Garcia J.M., Cata J.P., Dougherty P.M., Smith R.G. Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology 2008, 149:455-460.
95. Garcia J.M., Garcia-Touza M., Hijazi R.A., Taffet G., Epner D., Mann D., et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. The Journal of Clinical Endocrinology and Metabolism 2005, 90:2920-2926.
96. Garcia J.M., Polvino W.J. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: Results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. The Oncologist 2007, 12:594-600.
97. Garcia J.M., Polvino W.J. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Hormone & IGF Research 2009, 19:267-273.
98. Gielen S., Adams V., Möbius-Winkler S., Linke A., Erbs S., Yu J., et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. Journal of the American College of Cardiology 2003, 42:861-868.
99. Gonzalez-Rey E., Chorny A., Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 2006, 130:1707-1720.
100. Greenfield J.R., Miller J.W., Keogh J.M., Henning E., Satterwhite J.H., Cameron G.S., et al. Modulation of blood pressure by central melanocortinergic pathways. The New England Journal of Medicine 2009, 360:44-52.
101. Grossberg A.J., Scarlett J.M., Zhu X., Bowe D.D., Batra A.K., Braun T.P., et al. Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130. Endocrinology 2010, 151:606-616.
102. Hahn T.M., Breininger J.F., Baskin D.G., Schwartz M.W. Coexpression of agrp and NPY in fasting-activated hypothalamic neurons. Nature Neuroscience 1998, 1:271-272.
103. Hamilton J.A., Waring P.M., Filonzi E.L. Induction of leukemia inhibitory factor in human synovial fibroblasts by IL-1 and tumor necrosis factor-alpha. Journal of Immunology (Baltimore, Md.: 1950) 1993, 150:1496-1502.
104. Hanada T., Toshinai K., Kajimura N., Nara-Ashizawa N., Tsukada T., Hayashi Y., et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochemical and Biophysical Research Communications 2003, 301:275-279.
105. Haugen E., Tang M.S., Isic A., Andersson B., Fu M. TNF alpha antagonist upregulates interleukin-6 in rats with hypertensive heart failure. International Journal of Cardiology 2008, 130:64-68.
106. Heisler L.K., Cowley M.A., Kishi T., Tecott L.H., Fan W.E.I., Low M.J., et al. Central serotonin and melanocortin pathways regulating energy homeostasis. Annals of the New York Academy of Sciences 2003, 994:169-174.
107. Heisler L.K., Cowley M.A., Tecott L.H., Fan W., Low M.J., Smart J.L., et al. Activation of central melanocortin pathways by fenfluramine. Science 2002, 297:609-611.
108. Huang Q.H., Hruby V.J., Tatro J.B. Role of central melanocortins in endotoxin-induced anorexia. The American Journal of Physiology 1999, 276:R864-R871.
109. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88:131-141.
110. Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides-Mediation of the actions of leptin. Trends in Neurosciences 1999, 22:62-67.
111. Jatoi A., Rowland K., Loprinzi C.L., Sloan J.A., Dakhil S.R., MacDonald N., et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: A north central cancer treatment group and national cancer institute of Canada collaborative effort. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2004, 22:2469-2476.
112. Jiang W., Tucci F.C., Tran J.A., Fleck B.A., Wen J., Markison S., et al. Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor. Bioorganic & Medicinal Chemistry Letters 2007, 17:5610-5613.
113. Joppa M.A., Gogas K.R., Foster A.C., Markison S. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 2007, 28:636-642.
114. Kadokami T., Frye C., Lemster B., Wagner C.L., Feldman A.M., McTiernan C.F. Anti-tumor necrosis factor-α antibody limits heart failure in a transgenic model. Circulation 2001, 104:1094-1097.
115. Karmiris K., Koutroubakis I.E., Xidakis C., Polychronaki M., Voudouri T., Kouroumalis E.A. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflammatory Bowel Diseases 2006, 12:100-105.
116. Kaysen G.A., Rathore V., Shearer G.C., Depner T.A. Mechanisms of hypoalbuminemia in hemodialysis patients. Kidney International 1995, 48:510-516.
117. Kerem M., Ferahkose Z., Yilmaz U.T., Pasaoglu H., Ofluoglu E., Bedirli A., et al. Adipokines and ghrelin in gastric cancer cachexia. World Journal of Gastroenterology: WJG 2008, 14:3633-3641.
118. Kim H.J., Kim H.J., Yun J., Kim K.H., Kim S.H., Lee S.-C., et al. Pathophysiological role of hormones and cytokines in cancer cachexia. Journal of Korean Medical Science 2012, 27:128-134.
119. Knoll S., Zimmer S., Hinney A., Scherag A., Neubauer A., Hebebrand J. Val103Ile Polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia. BMC Cancer 2008, 8:85.
120. Kobayashi K. Role of catecholamine signaling in brain and nervous system functions: New insights from mouse molecular genetic study. The Journal of Investigative Dermatology. Symposium Proceedings 2001, 6:115-121.
121. Kodama T., Ashitani J.-I., Matsumoto N., Kangawa K., Nakazato M. Ghrelin treatment suppresses neutrophil-dominant inflammation in airways of patients with chronic respiratory infection. Pulmonary Pharmacology & Therapeutics 2008, 21:774-779.
122. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
123. Konturek P.C., Brzozowski T., Engel M., Burnat G., Gaca P., Kwiecien S., et al. Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves. Journal of Physiology and Pharmacology 2009, 60:41-47.
124. Kosmiski L. Energy expenditure in HIV infection. The American Journal of Clinical Nutrition 2011, 94:1677S-1682S.
125. Krakoff J., Ma L., Kobes S., Knowler W.C., Hanson R.L., Bogardus C., et al. Lower metabolic rate in individuals heterozygous for either a frameshift or a functional missense MC4R variant. Diabetes 2008, 57:3267-3272.
126. Lainscak M., Podbregar M., Anker S.D. How does cachexia influence survival in cancer, heart failure and other chronic diseases?. Current Opinion in Supportive and Palliative Care 2007, 1:299-305.
127. Langhans W. Peripheral mechanisms involved with catabolism. Current Opinion in Clinical Nutrition and Metabolic Care 2002, 5:419-426.
128. Larkin M. Thwarting the dwindling progression of cachexia. Lancet 1998, 351:1336.
129. Laviano A., Inui A., Meguid M.M., Molfino A., Conte C., Rossi Fanelli F. NPY and brain monoamines in the pathogenesis of cancer anorexia. Nutrition 2008, 24:802-805.
130. Le Goffic R., Mouchel T., Aubry F., Patard J.-J., Ruffault A., Jegou B., et al. Production of the chemokines monocyte chemotactic protein-1, regulated on activation normal T cell expressed and secreted protein, growth-related oncogene, and interferon-[gamma]-inducible protein-10 is induced by the Sendai virus in human and rat testicular cells. Endocrinology 2002, 143:1434-1440.
131. Lee C.W., Lin C.C., Lee I.T., Lee H.C., Yang C.M. Activation and induction of cytosolic phospholipase A(2) by TNF-alpha mediated through Nox2, MAPKs, NF-kappa B, and p300 in human tracheal smooth muscle cells. Journal of Cellular Physiology 2010, 226:2103-2114.
132. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. The New England Journal of Medicine 1990, 323:236-241.
133. Li W.G., Gavrila D., Liu X., Wang L., Gunnlaugsson S., Stoll L.L., et al. Ghrelin inhibits proinflammatory responses and nuclear factor-κB activation in human endothelial cells. Circulation 2004, 109:2221-2226.
134. Li Y.-P., Reid M.B. Effect of tumor necrosis factor-[alpha] on skeletal muscle metabolism. Current Opinion in Rheumatology 2001, 13:483-487.
135. Li G., Zhang Y., Rodrigues E., Zheng D., Matheny M., Cheng K.Y., et al. Melanocortin activation of nucleus of the solitary tract avoids anorectic tachyphylaxis and induces prolonged weight loss. American Journal of Physiology. Endocrinology and Metabolism 2007, 293:E252-E258.
136. Ling P.R., Schwartz J.H., Bistrian B.R. Mechanisms of host wasting induced by administration of cytokines in rats. American Journal of Physiology-Endocrinology and Metabolism 1997, 272:E333-E339.
137. Liu Y.L., Malik N., Sanger G., Andrews P. Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemotherapy and Pharmacology 2006, 58:326-333.
138. Lundholm K., Daneryd P., Bosaeus I., Körner U., Lindholm E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function. Cancer 2004, 100:1967-1977.
139. Lundholm K., Gelin J., Hyltander A., Lönnroth C., Sandström R., Svaninger G., et al. Anti-inflammatory treatment May prolong survival in undernourished patients with metastatic solid tumors. Cancer Research 1994, 54:5602-5606.
140. Lundholm K., Gunnebo L., Körner U., Iresjö B.-M., Engström C., Hyltander A., et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients. Cancer 2010, 116:2044-2052.
141. Madeddu C., Dessì M., Panzone F., Serpe R., Antoni G., Cau M.C., et al. Randomized phase III clinical trial of a combined treatment with carnitine+celecoxib±megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clinical Nutrition 2012, 31:176-182.
142. Madihally S.V.P., Toner M.P., Yarmush M.L.M.D.P., Mitchell R.N.M.D.P. Interferon gamma modulates trauma-induced muscle wasting and immune dysfunction. Annals of Surgery 2002, 236:649-657.
143. Madison L.D., Marks D.L. Anticatabolic properties of melanocortin-4 receptor antagonists. Current Opinion in Clinical Nutrition and Metabolic Care 2006, 9:196-200. 10.1097/1001.mco.0000222099.0000236632.0000222081.
144. Mak R.H., Cheung W., Cone R.D., Marks D.L. Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease. Pediatric Nephrology (Berlin, Germany) 2005, 20:427-431.
145. Mak R.H., Cheung W., Cone R.D., Marks D.L. Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney International 2006, 69:794-797.
146. Mak R.H., Cheung W., Cone R.D., Marks D.L. Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia. Nature Clinical Practice. Nephrology 2006, 2:527-534.
147. Mak R.H., Cheung W.W., Zhan J.Y., Shen Q., Foster B.J. Cachexia and protein-energy wasting in children with chronic kidney disease. Pediatric Nephrology (Berlin, Germany) 2012, 27:173-181.
148. Maltoni M., Nanni O., Pirovano M., Scarpi E., Indelli M., Martini C., et al. Successful validation of the palliative prognostic score in terminally Ill cancer patients. Journal of Pain and Symptom Management 1999, 17:240-247.
149. Markison S., Foster A.C., Chen C., Brookhart G.B., Hesse A., Hoare S.R.J., et al. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 2005, 146:2766-2773.
150. Marks D.L., Butler A.A., Turner R., Brookhart G., Cone R.D. Differential role of melanocortin receptor subtypes in cachexia. Endocrinology 2003, 144:1513-1523.
151. Marks D.L., Ling N., Cone R.D. Role of the central melanocortin system in cachexia. Cancer Research 2001, 61:1432-1438.
152. McMurray J., Abdullah I., Dargie H.J., Shapiro D. Increased concentrations of tumour necrosis factor in " cachectic" patients with severe chronic heart failure. British Heart Journal 1991, 66:356-358.
153. Melchior J.C., Raguin G., Boulier A., Bouvet E., Rigaud D., Matheron S., et al. Resting energy expenditure in human immunodeficiency virus-infected patients: Comparison between patients with and without secondary infections. The American Journal of Clinical Nutrition 1993, 57:614-619.
154. Metcalf D., Gearing D.P. A myelosclerotic syndrome in mice engrafted with cells producing high levels of leukemia inhibitory factor (LIF). Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 1989, 3:847-852.
155. Metcalf D., Nicola N.A., Gearing D.P. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 1990, 76:50-56.
156. Michalaki V. The prognostic significance of serum levels of tumour necrosis factor-alpha and interleukin-6 and their association with cachexia in patients with prostate cancer. Journal of Clinical Oncology 2004, 22:4743.
157. Michie H.R., Manogue K.R., Spriggs D.R., Revhaug A., O'Dwyer S., Dinarello C.A., et al. Detection of circulating tumor necrosis factor after endotoxin administration. The New England Journal of Medicine 1988, 318:1481-1486.
158. Minutoli L., Squadrito F., Nicotina P.A., Giuliani D., Ottani A., Polito F., et al. Melanocortin 4 receptor stimulation decreases pancreatitis severity in rats by activation of the cholinergic anti-inflammatory pathway. Critical Care Medicine 2011, 39:1089-1096.
159. Mitch W. Mechanisms causing loss of lean body mass in kidney disease. The American Journal of Clinical Nutrition 1998, 67:359-366.
160. Mori T., Miyamoto T., Yoshida H., Asakawa M., Kawasumi M., Kobayashi T., et al. IL-1beta and TNFalpha-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. International Immunology 2011, 23:701-712.
161. Moyle G.J., Daar E.S., Gertner J.M., Kotler D.P., Melchior J.-C., O'Brien F., et al. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 2004, 35:367-375.
162. Müller M.J., Lautz H.U., Plogmann B., Bürger M., Körber J., Schmidt F.W. Energy expenditure and substrate oxidation in patients with cirrhosis: The impact of cause, clinical staging and nutritional state. Hepatology 1992, 15:782-794.
163. Nagaya N., Itoh T., Murakami S., Oya H., Uematsu M., Miyatake K., et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005, 128:1187-1193.
164. Nagaya N., Moriya J., Yasumura Y., Uematsu M., Ono F., Shimizu W., et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004, 110:3674-3679.
165. Nagaya N., Uematsu M., Kojima M., Date Y., Nakazato M., Okumura H., et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure. Circulation 2001, 104:2034-2038.
166. Nagaya N., Uematsu M., Kojima M., Date Y., Nakazato M., Okumura H., et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: Relationships between ghrelin and anabolic/catabolic factors. Circulation 2001, 104:2034-2038.
167. Nagaya N., Uematsu M., Kojima M., Ikeda Y., Yoshihara F., Shimizu W., et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001, 104:1430-1435.
168. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., et al. A role for ghrelin in the central regulation of feeding. Nature 2001, 409:194-198.
169. Nass R., Pezzoli S.S., Oliveri M.C., Patrie J.T., Harrell F.E., Clasey J.L., et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: A randomized trial. Annals of Internal Medicine 2008, 149:601-611.
170. Naufel M.F., Bordon M., de Aquino T.M., Ribeiro E.B., de Abreu Carvalhaes J.T. Plasma levels of acylated and total ghrelin in pediatric patients with chronic kidney disease. Pediatric Nephrology (Berlin, Germany) 2010, 25:2477-2482.
171. Neary N.M., Small C.J., Wren A.M., Lee J.L., Druce M.R., Palmieri C., et al. Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2004, 89:2832-2836.
172. Nicholson J.R., Kohler G., Schaerer F., Senn C., Weyermann P., Hofbauer K.G. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. Journal of Pharmacology and Experimental Therapeutics 2006, 317:771-777.
173. Nijenhuis W.A.J., Oosterom J., Adan R.A.H. AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Molecular Endocrinology 2001, 15:164-171.
174. Ollmann M.M., Wilson B.D., Yang Y.-K., Kerns J.A., Chen Y., Gantz I., et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997, 278:135-138.
175. Palenicek J.P., Graham N.M., He Y.D., Hoover D.A., Oishi J.S., Kingsley L., et al. Weight loss prior to clinical AIDS as a predictor of survival. Multicenter AIDS Cohort Study Investigators. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology: Official Publication of the International Retrovirology Association 1995, 10:366-373.
176. Palus S., Schur R., Akashi Y.J., Bockmeyer B., Datta R., Halem H., et al. Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a Rat heart failure model. PLoS One 2011, 6:e26865.
177. Paton N.I., Newton P.J., Sharpstone D.R., Ross H.M., Cotton J., Calder A.G., et al. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. AIDS (London, England) 1999, 13:1195-1202.
178. Payne C., Wiffen P.J., Martin S. Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane Database of Systematic Reviews (Online) 2012, 1:CD008427.
179. Peruhype-Magalhaes V., Martins-Filho O.A., Prata A., Silva L.De.A., Rabello A., Teixeira-Carvalho A., et al. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-[gamma] and interleukin-10 and low frequency of tumour necrosis factor-[alpha]+monocytes are hallmarks of active human visceral leishmaniasis due to leishmania chagasi infection. Clinical and Experimental Immunology 2006, 146(1):124-132.
180. Pinder R.M., Brogden R.N., Sawyer P.R., Speight T.M., Avery G.S. Fenfluramine: A review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 1975, 10:241-323.
181. Pittman J.G., Cohen P. The pathogenesis of cardiac cachexia. The New England Journal of Medicine 1964, 271:453-460.
182. Plata-Salamán C.R., Oomura Y., Kai Y. Tumor necrosis factor and interleukin-1β: Suppression of food intake by direct action in the central nervous system. Brain Research 1988, 448:106-114.
183. Qureshi A.R., Alvestrand A., Divino-Filho J.C., Gutierrez A., Heimburger O., Lindholm B., et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. Journal of the American Society of Nephrology: JASN 2002, 13(Suppl. 1):S28-S36.
184. Rajan D., Wu R., Shah K.G., Jacob A., Coppa G.F., Wang P. Human ghrelin protects animals from renal ischemia-reperfusion injury through the vagus nerve. Surgery 2012, 151:37-47.
185. Rammohan M., Kalantar-Zadeh K., Liang A., Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. Journal of Renal Nutrition: The Official Journal of the Council on Renal Nutrition of the National Kidney Foundation 2005, 15:345-355.
186. Ramos E.J., Suzuki S., Marks D., Inui A., Asakawa A., Meguid M.M. Cancer anorexia-cachexia syndrome: Cytokines and neuropeptides. Current Opinion in Clinical Nutrition and Metabolic Care 2004, 7:427-434.
187. Rasic-Milutinovic Z., Perunicic G., Pljesa S., Gluvic Z., Sobajic S., Djuric I., et al. Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients. Renal Failure 2007, 29:321-329.
188. Reid M.B., Li Y.P. Cytokines and oxidative signalling in skeletal muscle. Acta Physiologica Scandinavica 2001, 171:225-232.
189. Rodriguez A., Gomez-Ambrosi J., Catalan V., Becerril S., Sainz N., Gil M.J., et al. Association of plasma acylated ghrelin with blood pressure and left ventricular mass in patients with metabolic syndrome. Journal of Hypertension 2010, 28:560-567.
190. Scarlett J.M., Bowe D.D., Zhu X., Batra A.K., Grant W.F., Marks D.L. Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure. Journal of Endocrinology 2010, 206:121-130.
191. Scarlett J.M., Jobst E.E., Enriori P.J., Bowe D.D., Batra A.K., Grant W.F., et al. Regulation of central melanocortin signaling by interleukin-1 beta. Endocrinology 2007, 148:4217-4225.
192. Scarlett J.M., Zhu X., Enriori P.J., Bowe D.D., Batra A.K., Levasseur P.R., et al. Regulation of agouti-related protein messenger ribonucleic acid transcription and peptide secretion by acute and chronic inflammation. Endocrinology 2008, 149:4837-4845.
193. Schambelan M., Mulligan K., Grunfeld C., Daar E.S., LaMarca A., Kotler D.P., et al. Recombinant human growth hormone in patients with HIV-associated wasting. Annals of Internal Medicine 1996, 125:873-882.
194. Schwartz M.W. Central nervous system control of food intake. Nature (London) 2000, 404:661.
195. Schwartz M.W., Seeley R.J., Woods S.C., Weigle D.S., Campfield L.A., Burn P., et al. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 1997, 46:2119-2123.
196. Schwenke D.O., Tokudome T., Kishimoto I., Horio T., Shirai M., Cragg P.A., et al. Early ghrelin treatment after myocardial infarction prevents an increase in cardiac sympathetic tone and reduces mortality. Endocrinology 2008, 149:5172-5176.
197. Seoane L.M., Lopez M., Tovar S., Casanueva F.F., Senaris R., Dieguez C. Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology 2003, 144:544-551.
198. Sethi J.K., Hotamisligil G.S. The role of TNFα in adipocyte metabolism. Seminars in Cell & Developmental Biology 1999, 10:19-29.
199. Sheriff S., Joshi R., Friend L.A., James J.H., Balasubramaniam A. Ghrelin receptor agonist, GHRP-2, attenuates burn injury-induced MuRF-1 and MAFbx expression and muscle proteolysis in rats. Peptides 2009, 30:1909-1913.
200. Sheriff S., Kadeer N., Joshi R., Friend L.A., Howard James J., Balasubramaniam A. Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats. Molecular and Cellular Endocrinology 2012, 351:286-295.
201. Shevitz A.H., Knox T.A., Spiegelman D., Roubenoff R., Gorbach S.L., Skolnik P.R. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS (London, England) 1999, 13:1351-1357.
202. Shiiya T., Nakazato M., Mizuta M., Date Y., Mondal M.S., Tanaka M., et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. Journal of Clinical Endocrinology and Metabolism 2002, 87:240-244.
203. Shimizu Y., Nagaya N., Isobe T., Imazu M., Okumura H., Hosoda H., et al. Increased plasma ghrelin level in lung cancer cachexia. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2003, 9:774-778.
204. Shinaberger C.S., Kilpatrick R.D., Regidor D.L., McAllister C.J., Greenland S., Kopple J.D., et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. American Journal of Kidney Diseases 2006, 48:37-49.
205. Simons J.P., Schols A.M., Hoefnagels J.M., Westerterp K.R., ten Velde G.P., Wouters E.F. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: A randomized, placebo-controlled trial. Cancer 1998, 82:553-560.
206. Sinno M.H., Coquerel Q., Boukhettala N., Coëffier M., Gallas S., Terashi M., et al. Chemotherapy-induced anorexia is accompanied by activation of brain pathways signaling dehydration. Physiology & Behavior 2010, 101:639-648.
207. Sirotkin A.V., Chrenkova M., Nitrayova S., Patras P., Darlak K., Valenzuela F., et al. Effects of chronic food restriction and treatments with leptin or ghrelin on different reproductive parameters of male rats. Peptides 2008, 29:1362-1368.
208. Soeki T., Kishimoto I., Schwenke D.O., Tokudome T., Horio T., Yoshida M., et al. Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology 2008, 294:H426-H432.
209. Sonti G., Ilyin S.E., Plata-Salaman C.R. Anorexia induced by cytokine interactions at pathophysiological concentrations. The American Journal of Physiology 1996, 270:R1394-R1402.
210. Soriano-Guillén L., Barrios V., Campos-Barros á., Argente J. Ghrelin levels in obesity and anorexia nervosa: Effect of weight reduction or recuperation. The Journal of Pediatrics 2004, 144:36-42.
211. Springer J., Filippatos G., Akashi Y.J., Anker S.D. Prognosis and therapy approaches of cardiac cachexia. Current Opinion in Cardiology 2006, 21:229-233. 10.1097/1001.hco.0000221585.0000294490.0000221509.
212. Sreedhara R., Avram M.M., Blanco M., Batish R., Mittman N. Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation 1996, 28:937-942.
213. Srisai D., Gillum M.P., Panaro B.L., Zhang X.M., Kotchabhakdi N., Shulman G.I., et al. Characterization of the hyperphagic response to dietary fat in the MC4R knockout mouse. Endocrinology 2011, 152:890-902.
214. Stanley T., Grinspoon S. GH/GHRH axis in HIV lipodystrophy. Pituitary 2009, 12:143-152.
215. Stengel A., Goebel M., Wang L., Reeve J.R., Tache Y., Lambrecht N.W. Lipopolysaccharide differentially decreases plasma acyl and desacyl ghrelin levels in rats: Potential role of the circulating ghrelin-acylating enzyme GOAT. Peptides 2010, 31:1689-1696.
216. Straburzynska-Migaj E., Gwizdala A., Siniawski A., Ochotny R., Grajek S. Leptin and inflammation in patients with chronic heart failure. Kardiologia Polska 2010, 68:1243-1247.
217. Strasser F., Lutz T.A., Maeder M.T., Thuerlimann B., Bueche D., Tschop M., et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: A randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer 2008, 98:300-308.
218. Strassmann G. Role of interleukin-6 in experimental cancer cachexia. Journal of Immunotherapy 1993, 13:73.
219. Strassmann G., Fong M., Kenney J.S., Jacob C.O. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. The Journal of Clinical Investigation 1992, 89:1681-1684.
220. Sutton G.M., Josephine Babin M., Gu X., Hruby V.J., Butler A.A. A derivative of the melanocortin receptor antagonist SHU9119 (PG932) increases food intake when administered peripherally. Peptides 2008, 29:104-111.
221. Suzuki H., Hashimoto H., Kawasaki M., Watanabe M., Otsubo H., Ishikura T., et al. Similar changes of hypothalamic feeding-regulating peptides mRNAs and plasma leptin levels in PTHrP-, LIF-secreting tumors-induced cachectic rats and adjuvant arthritic rats. International Journal of Cancer 2011, 128:2215-2223.
222. Swanson L.W., Sawchenko P.E. Paraventricular nucleus: A site for the integration of neuroendocrine and autonomic mechanisms. Neuroendocrinology 1980, 31:410-417.
223. Szklarek-Kubicka M., Fijalkowska-Morawska J., Zaremba-Drobnik D., Ucinski A., Czekalski S., Nowicki M. Effect of intradialytic intravenous administration of omega-3 fatty acids on nutritional status and inflammatory response in hemodialysis patients: A pilot study. Journal of Renal Nutrition: The Official Journal of the Council on Renal Nutrition of the National Kidney Foundation 2009, 19:487-493.
224. Takeda H., Muto S., Hattori T., Sadakane C., Tsuchiya K., Katsurada T., et al. Rikkunshito ameliorates the aging-associated decrease in ghrelin receptor reactivity via phosphodiesterase III inhibition. Endocrinology 2010, 151:244-252.
225. Takeda R., Nishimatsu H., Suzuki E., Satonaka H., Nagata D., Oba S., et al. Ghrelin improves renal function in mice with ischemic acute renal failure. Journal of the American Society of Nephrology: JASN 2006, 17:113-121.
226. Theander-Carrillo C., Wiedmer P., Cettour-Rose P., Nogueiras R., Perez-Tilve D., Pfluger P., et al. Ghrelin action in the brain controls adipocyte metabolism. The Journal of Clinical Investigation 2006, 116:1983-1993.
227. Thibault R., Cano N., Pichard C. Quantification of lean tissue losses during cancer and HIV infection/AIDS. Current Opinion in Clinical Nutrition and Metabolic Care 2011, 14:261-267.
228. Tisdale M.J. Biology of cachexia. Journal of the National Cancer Institute 1997, 89:1763-1773.
229. Tisdale M.J. Clinical anticachexia treatments. Nutrition in Clinical Practice 2006, 21:168-174.
230. Tisdale M.J. Mechanisms of cancer cachexia. Physiological Reviews 2009, 89:381-410.
231. Tisdale M.J. Cancer cachexia. Current Opinion in Gastroenterology 2010, 26:146-151.
232. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). Journal of the American College of Cardiology 1996, 27:1201-1206.
233. Torre-Amione G., Kapadia S., Lee J., Durand J.-B., Bies R.D., Young J.B., et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704-711.
234. Torre-Amione G., Stetson S.J., Youker K.A., Durand J.-B., Radovancevic B., Delgado R.M., et al. Decreased expression of tumor necrosis factor-α in failing human myocardium after mechanical circulatory support: A potential mechanism for cardiac recovery. Circulation 1999, 100:1189-1193.
235. Toshinai K., Mondal M.S., Shimbara T., Yamaguchi H., Date Y., Kangawa K., et al. Ghrelin stimulates growth hormone secretion and food intake in aged rats. Mechanisms of Ageing and Development 2007, 128:182-186.
236. Tran J.A., Jiang W., Tucci F.C., Fleck B.A., Wen J., Sai Y., et al. Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor. Journal of Medicinal Chemistry 2007, 50:6356-6366.
237. Tritos N.A., Vicent D., Gillette J., Ludwig D.S., Flier E.S., Maratos-Flier E. Functional interactions between melanin-concentrating hormone, neuropeptide Y, and anorectic neuropeptides in the rat hypothalamus. Diabetes 1998, 47:1687-1692.
238. Trobec K., von Haehling S., Anker S.D., Lainscak M. Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia. Journal of Cachexia Sarcopenia Muscle 2011, 2:191-200.
239. Trop M., Schintler M., Spendel S., Stockenhuber A. Unhealed wounds, hypoalbuminemia and cachexia in a burned child-Where is the limit?. Annals of Burns and Fire Disasters 2008, 21:59-62.
240. Tsai J.-S., Wu C.-H., Chiu T.-Y., Hu W.-Y., Chen C.-Y. Symptom patterns of advanced cancer patients in a palliative care unit. Palliative Medicine 2006, 20:617-622.
241. Tschop M., Smiley D.L., Heiman M.L. Ghrelin induces adiposity in rodents. Nature 2000, 407:908-913.
242. Vernaglione L., Cristofano C., Chimienti S. Omega-3 polyunsaturated fatty acids and proxies of cardiovascular disease in hemodialysis: A prospective cohort study. Journal of Nephrology 2008, 21:99-105.
243. 2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology 2003, 167:274-280.
244. Villiger P.M., Geng Y., Lotz M. Induction of cytokine expression by leukemia inhibitory factor. The Journal of Clinical Investigation 1993, 91:1575-1581.
245. von Haehling S., Anker S.D. Cachexia as a major underestimated and unmet medical need: Facts and numbers. Journal of Cachexia Sarcopenia Muscle 2010, 1:1-5.
246. von Haehling S., Stepney R., Anker S.D. Advances in understanding and treating cardiac cachexia: Highlights from the 5th cachexia conference. International Journal of Cardiology 2010, 144:347-349. 2010 Elsevier Ireland Ltd, Netherlands.
247. Vos T.J., Caracoti A., Che J.L., Dai M., Farrer C.A., Forsyth N.E., et al. Identification of 2-{2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl}-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. Journal of Medicinal Chemistry 2004, 47:1602-1604.
248. Voss-Andreae A., Murphy J.G., Ellacott K.L., Stuart R.C., Nillni E.A., Cone R.D., et al. Role of the central melanocortin circuitry in adaptive thermogenesis of brown adipose tissue. Endocrinology 2007, 148:1550-1560.
249. Wang W., Andersson M., Iresjo B.M., Lonnroth C., Lundholm K. Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia. International Journal of Oncology 2006, 28:1393-1400.
250. Wang H., Huang Z., Huang L., Niu S., Rao X., Xu J., et al. Hypothalamic Ahi1 mediates feeding behavior through interaction with 5-HT2C receptor. Journal of Biological Chemistry 2012, 287:2237-2246.
251. Wang A.Y., Sea M.M., Tang N., Sanderson J.E., Lui S.F., Li P.K., et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. Journal of the American Society of Nephrology: JASN 2004, 15:3134-3143.
252. Wellhoner P., Horster R., Jacobs F., Sayk F., Lehnert H., Dodt C. Intranasal application of the melanocortin 4 receptor agonist MSH/ACTH(4-10) in humans causes lipolysis in white adipose tissue. International Journal of Obesity 2011, 36:703-708.
253. Weyermann P., Dallmann R., Magyar J., Anklin C., Hufschmid M., Dubach-Powell J., et al. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS One 2009, 4:e4774.
254. Whitaker K.W., Reyes T.M. Central blockade of melanocortin receptors attenuates the metabolic and locomotor responses to peripheral interleukin-1β administration. Neuropharmacology 2008, 54:509-520.
255. Wilson B.D., Bagnol D., Kaelin C.B., Ollmann M.M., Gantz I., Watson S.J., et al. Physiological and anatomical circuitry between agouti-related protein and leptin signaling. Endocrinology 1999, 140:2387-2397.
256. Wisse B.E., Frayo R.S., Schwartz M.W., Cummings D.E. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001, 142:3292-3301.
257. Wren A.M., Small C.J., Ward H.L., Murphy K.G., Dakin C.L., Taheri S., et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000, 141:4325-4328.
258. Wu R., Dong W., Zhou M., Zhang F., Marini C.P., Ravikumar T.S., et al. Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. American Journal of Respiratory and Critical Care Medicine 2007, 176:805-813.
259. Wynne K., Giannitsopoulou K., Small C.J., Patterson M., Frost G., Ghatei M.A., et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: A randomized, placebo-controlled trial. Journal of the American Society of Nephrology 2005, 16:2111-2118.
260. Xu Y., Jones J.E., Kohno D., Williams K.W., Lee C.E., Choi M.J., et al. 5-HT2CRs expressed by Pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 2008, 60:582-589.
261. Yamamoto K., Takiguchi S., Miyata H., Adachi S., Hiura Y., Yamasaki M., et al. Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. Surgery 2010, 148:31-38.
262. Yamashita J.-i., Ogawa M. Medroxyprogesterone acetate and cancer cachexia: Interleukin-6 involvement. Breast Cancer 2000, 7:130-135.
263. Yang Q., Berthiaume F., Androulakis I.P. A quantitative model of thermal injury-induced acute inflammation. Mathematical Biosciences 2011, 229:135-148.
264. Yoshimoto A., Mori K., Sugawara A., Mukoyama M., Yahata K., Suganami T., et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. Journal of the American Society of Nephrology: JASN 2002, 13:2748-2752.
265. Zhang F., Basinski M.B., Beals J.M., Briggs S.L., Churgay L.M., Clawson D.K., et al. Crystal structure of the obese protein leptin-E100. Nature 1997, 387:206-209.